Recherches "plusieurs pathologies"
EXPRESS
Low level of genomic alteration to predict exceptional and unexpected response to targeted thÚrapies in patients with solid tumors.;EXPRESS : EXcePtional RESponSe
Paris
CHRISTOPHE LE TOURNEAU
Prostate
MK3475-365
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Paris
Sein métastatique RH+
SAFIR-TOR
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women.
Paris, Saint-Cloud
PAUL-HENRI COTTU
Sein Néoadjuvant
ALIENOR
Detection of Circulating Tumoral DNA Mutations (Sequential Assessment) Following Neoadjuvant Chemotherapy for Breast Cancer: Clinical Validity (ALIENOR Study)
Paris, Saint-Cloud
Appareil pulmonaire
BP40657
A TWO-PART PHASE Ib/II STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS IN PATIENTS WITH STAGE IV;NONÀSMALL CELL LUNG CANCER
Paris
Appareil pulmonaire
AMG20190294
A Non-interventional Biomarker Study on the;Molecular Evaluation of Archival Tumor Tissue in;Subjects with Non-Small Cell Lung Cancer;(NSCLC)
Paris
NICOLAS GIRARD